Alteration of bone biochemical markers in children with CML undergoing imatinib treatment. There is a significant (p = 0.011) decline in bone resorption over time, as indicated by urine desoxypyridinolin (DPD). However, in most cases, values are still in the lower normal range. Bone formation as indicated by osteocalcin levels is impaired, with most values below the lower normal range and exhibiting a borderline significant (p = 0.041) decline over time.⁴⁴